Skip to main content
Premium Trial:

Request an Annual Quote

Abbott, Pfizer Partner on Companion Dx for Cancer Drug

NEW YORK (GenomeWeb News) – Abbott yesterday said that it will partner with Pfizer on a molecular diagnostic test to screen non-small cell lung cancer tumors for the presence of gene rearrangements.

Pfizer is developing a drug that selectively targets cancer-causing genes implicated in the progress of many cancers, the firms said in a statement. For patients to be eligible to receive the drug candidate, a particular genetic translocation known to be present in NSCLC tumors and others cancers, but not in normal cells, must be identified in the tumor sample.

Abbott will develop a companion diagnostic test that will determine if a patient's genetic status makes them eligible for selection in future clinical trials of the compound, PF-02341066.

"Pfizer's novel compound for treating non-small cell lung cancer appears to be ideally suited to individualized therapy," said Stafford O'Kelly, head of Abbott's molecular diagnostics business, in a statement.

The Scan

Single-Cell Sequencing Points to Embryo Mosaicism

Mosaicism may affect preimplantation genetic tests for aneuploidy, a single-cell sequencing-based analysis of almost three dozen embryos in PLOS Genetics finds.

Rett Syndrome Mouse Model Study Points to RNA Editing Possibilities

Investigators targeted MECP2 in mutant mouse models of Rett syndrome, showing in PNAS that they could restore its expression and dial down symptoms.

Investigators Find Shared, Distinct Genetic Contributors to Childhood Hodgkin Lymphoma

An association study in JAMA Network Open uncovers risk variants within and beyond the human leukocyte antigen locus.

Transcriptomic, Epigenetic Study Appears to Explain Anti-Viral Effects of TB Vaccine

Researchers report in Science Advances on an interferon signature and long-term shifts in monocyte cell DNA methylation in Bacille Calmette-Guérin-vaccinated infant samples.